SOLIUS Announces Investment from Human Longevity Inc. to Support Mission of Improving Health, Performance, and Longevity

May 13, 2020

SOLIUS, a developer of innovative light therapy technologies focused on mitigating vitamin D deficiency, today announced investment from Human Longevity, Inc. (HLI) into its Series B financing.

The SOLIUS technology stimulates the production of vitamin D in the skin using a narrow spectrum of ultraviolet B (UVB) light. Vitamin D has a wide range of impact on systemic health, and supports physical, mental and immune function. SOLIUS delivers safe and effective light therapy using a personalized dosing system while filtering out nearly all other ultraviolet light. The SOLIUS technology can produce 10x more vitamin D than the sun, using 100x less ultraviolet energy. This technology is also an effective solution for at risk populations unable to absorb vitamin D orally.

HIL is a pioneer and leader in the delivery of data-driven, predictive precision health intelligence. Wei-Wu He, PhD, Executive Chairman, HLI stated: “We are excited to invest in SOLIUS as its mission is to provide the benefits of the sun without the harmful rays to unlock the healing powers of the human body. Investing in SOLIUS is another example of HLI’s expertise in aggregating and leveraging technologies designed to demonstrably increase health, performance and lifespan. I welcome SOLIUS to our emerging ecosystem of longevity and performance-focused companies.”

Bob Wise, SOLIUS CEO, said “Humans need sun exposure to stay healthy, and the benefits of the sun cannot be fully replicated with hormone replacement, such as oral vitamin D supplements. We are excited to partner with HLI in developing technologies that prevent disease and improve human health.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy